Abstract
6-Keto-prostaglandin (PG) E1 has been suggested as a possible active metabolite of PGI2. The objective of this study was to evaluate whether 6-keto-PGE1 might mediate the biological responses of exogenous PGI2 in man. Toward this end, a novel gas chromatographic-mass spectrometric assay for 6-keto-PGE1, was developed. Selective ion monitor traces from human plasma detected levels that were at the lower limit of sensitivity for this assay and positive mass spectral identification was not possible. An infusion of PGI2 (8 ng/kg/min) which caused systemic hemodynamic changes did not alter plasma levels of 6-keto-PGE1. We conclude that exogenous PGI2 is not converted to an appreciable extent to 6-keto-PGE1 in man and, therefore, 6-keto-PGE1 biosynthesis is unlikely to be responsible for the biological effects of infused PGI2.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|